USA v. Holmes et al
Case Number:
5:18-cr-00258
Court:
Nature of Suit:
Judge:
Firms
-
October 15, 2021
Theranos' Test Demo Hid Failures From Investors, Jury Told
A former Theranos senior project manager testified in ex-Theranos CEO Elizabeth Holmes' criminal fraud trial Friday that he gave potential investors tours of the startup's headquarters and helped set up demonstrations using Theranos' blood-testing devices, which were, on at least one occasion, programmed to shield protocol failures.
-
October 14, 2021
Holmes Prayed As WSJ Reporter Raised Doubts, Jury Told
A California federal magistrate judge Thursday rejected ex-Theranos CEO Elizabeth Holmes' efforts to exclude ex-Wall Street Journal reporter and "Bad Blood" author John Carreyrou from watching her criminal fraud trial, while the jury viewed text messages showing she was "praying literally nonstop" as Carreyrou's investigation raised doubts about Theranos' technology.
-
October 13, 2021
Ex-Walgreens Exec Told Holmes 'Haters Are Everywhere'
Former Walgreen Co. Chief Financial Officer Wade Miquelon testified in ex-Theranos CEO Elizabeth Holmes' criminal fraud trial Wednesday that he encouraged Walgreens' CEO to enter a $140 million deal with the blood-testing startup and tried to comfort Holmes as Theranos faced public scrutiny, writing her in 2015 that "haters are everywhere."
-
October 12, 2021
Latham Helped Vet Theranos Deal, Ex-Safeway CEO Says
Safeway's former CEO Steven Burd testified under cross-examination from Elizabeth Holmes' attorney on Tuesday that the grocery chain hired Latham & Watkins LLP to help conduct due diligence on Theranos before agreeing to their $55 million deal, and confirmed that the firm helped him prepare for testifying.
-
October 06, 2021
Ex-Safeway CEO Says Theranos Didn't Deliver On $55M Deal
Former Safeway CEO Steven Burd testified in ex-Theranos CEO Elizabeth Holmes' criminal fraud trial Wednesday that he was initially impressed by Holmes' "charisma" and Theranos' technology, but two years after Holmes "almost exclusively" negotiated her company's $55 million deal with the grocery chain, he was frustrated Theranos hadn't delivered.
-
October 05, 2021
Ex-Theranos Lab Chief Says Ebola Rumor Was 'Final Straw'
A former Theranos lab director testified in ex-Theranos CEO Elizabeth Holmes' criminal trial Tuesday that he told Holmes he no longer wanted to serve as its lab director in 2014 after hearing Theranos was rumored to be doing Ebola tests, calling it the "final straw."
-
October 01, 2021
Ex-Theranos Lab Chief Testifies That Balwani Wasn't Qualified
A former Theranos lab director testified in ex-CEO Elizabeth Holmes' criminal fraud trial Friday that Holmes' onetime romantic partner Ramesh "Sunny" Balwani directed lab team members, ordered quality control studies and assessed the quality of Theranos data even though he wasn't qualified to do so.
-
September 29, 2021
Celgene Ended Theranos Deal Early Over Bad Data, Jury Told
A former Celgene senior scientist testified in ex-Theranos CEO Elizabeth Holmes' criminal fraud trial Wednesday that the pharmaceutical company cut short its deal with Theranos to help it in clinical trial testing after a Celgene study revealed wide variations between Theranos' blood tests and competitors' results.
-
September 28, 2021
Holmes Texts Show Investor Cash Poured In As Lab Struggled
A California federal jury deciding ex-Theranos CEO Elizabeth Holmes' criminal fraud trial saw text messages Tuesday between Holmes and her onetime romantic partner Ramesh "Sunny" Balwani revealing the pair raised over $250 million from prominent investors, including News Corp. founder Rupert Murdoch, days after Theranos' lab director quit over compliance concerns.
-
September 24, 2021
Theranos Execs Put PR Over Patients, Ex-Lab Chief Testifies
A former Theranos laboratory director testified in ex-CEO Elizabeth Holmes' criminal trial Friday that he resigned after company executives insisted on rolling out blood-testing devices riddled with technical problems that caused serious inaccuracies, saying management "believed more about PR and funding than about patient care."